NERVGEN PHARMA CORP. Annual Report - How They Did This Year

I’ve put together this guide to help you understand NervGen Pharma Corp.’s performance over the past year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

NervGen is a biotech company in the testing phase. Think of them as a lab working to turn a scientific discovery into a medicine. They focus on nerve repair for conditions like spinal cord injuries, Alzheimer’s, and multiple sclerosis. Because they are still testing, they have no products to sell. They generated $0 in revenue for the year ending December 31, 2023, and reported a loss of approximately $16.3 million CAD.

2. Financial health: The "Burn Rate"

Since NervGen isn't selling products, they don't have a profit. Instead, they have a "burn rate"—the speed at which they spend their cash to keep research moving.

• The Reality: As of December 31, 2023, the company held about $13.5 million CAD in cash. With annual spending of roughly $15 million, they need more money to operate beyond the next 12 months.
• The Strategy: To keep going, they sell new shares to investors. In 2023, they raised about $23 million CAD this way. While this keeps the company running, it results in more shares being issued, which reduces your ownership percentage and can lower the value of your existing shares.

3. Major wins and challenges

• The Lead Candidate (NVG-291): The company’s future depends on one drug, NVG-291. They are currently running the "CONNECT SCI Study," a clinical trial testing the drug’s safety and effectiveness in patients with spinal cord injuries.
• Regulatory Hurdles: The FDA previously placed a "partial clinical hold" on the drug, requiring extra safety monitoring. While they have addressed these concerns, any future safety issues could cause more delays.
• Operational Risks: The company must now prove it can handle large-scale trials and complex manufacturing. There is also a risk that the promising results they saw in animal tests will not work the same way in humans.

4. Key risks: What could go wrong?

Investing in NervGen is a high-stakes bet on their science. Beyond trial results, consider these hurdles:

• The "All-or-Nothing" Nature: Because they have no other products, if NVG-291 fails, the company’s value could drop significantly. There is no other business to fall back on.
• Regulatory & Legal Complexity: The company relies on its patents. If they fail to protect their intellectual property, competitors could copy their work, destroying their market advantage.
• Growing Pains: By 2027, the company will face stricter U.S. reporting rules. This will increase their legal and accounting costs, further straining their cash.
• Market Volatility: Without sales, the stock price moves entirely based on news and investor feelings. Expect big price swings based on trial updates or financing news.

Bottom Line: This is a high-risk investment. You aren't buying a business based on sales; you are betting on whether their technology can pass clinical testing and FDA approval. Before investing, ask yourself if you are comfortable with the possibility of share dilution and the reality that the company’s entire value rests on the success of a single clinical trial.